Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Acumen Pharmaceuticals, Inc.

35 indications, side-by-side phase, drug & LoA

$2.37

-0.02 (-0.84%)

D 37Pipeline Score Overvalued Biotech · Clinical
Market Cap
171.18 M
EPS
-1.86
P/E Ratio
-1.28 $
Value Trade
697.98 K
SEC Financials
Q1 2026

  • Dilution Risk

    35%

  • R&D Expenses

    16.48 M

  • Operating CF

    -24.13 M

  • Total Assets

    133.63 M

  • Total Liabilities

    46.15 M

  • Equity

    87.48 M

  • D/E Ratio

    12,345

6.81 %
Week
-9.06 %
1 Month
-6.34 %
3 Month
61.94 %
6 Month
-89.99 %
5 Year
-89.99 %
All Time
Cash Data
Stable

  • Cash Position

    128.40 M

  • Monthly Burn

    8.04 M

  • Runway

    15 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
414.94 K
52 Week Range
1 - 3.60
% held by Insiders
14.55 %
% held by Institutions
56.52 %
Enterprise Value
73.94 M
Total Shares
72.26 M
Short %
5.06 %
Float Shares
37.43 M
Company Description
HQ: 1210-1220 WASHINGTON STREET, N...
Founded:1996
Employees:61
https://www.acumenpharm.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 2 data readout example
sabirnetug (ACU193) Alzheimer's disease
Phase 2
—
Biologics
Nervous System
sabirnetug (ACU193) Alzheimer's disease
Phase 2
—
Biologics
Nervous System
sabirnetug (ACU193) Alzheimer's disease
Phase 2
—
Biologics
Nervous System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D37
Pipeline Score
$52M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 46%
Micro Cap
(rank 490 of 905)
Percentile Rank
Acumen Pharmaceuticals, Inc. faces pipeline headwinds (37/100), with $510M risk-adjusted pipeline value, led by sabirnetug in Alzheimer Disease (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
sabirnetug
Small molecule		Alzheimer DiseasePhase 2NCT0633517321% $372M ACTIVE NOT_RECRUITING 570 VERY_FAST A (84) Oct 1, 2026MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
sabirnetug (ACU193)
Alzheimer's disease
Phase 2
2025-07-16
sabirnetug (ACU193)
Alzheimer's disease
Phase 2
2025-07-16
sabirnetug (ACU193)
Alzheimer's disease
Phase 2
2025-07-16
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ABOS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ABOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ABOS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ABOS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-10-160 0.00 0 0 - - - - - -
2026-10-160 0.00 0 0 - - - - - -
2026-10-160 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Acumen Pharmaceuticals, Inc. (ABOS) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ABOS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Alzheimer's Disease #11 of 24 PHASE 2 sabirnetug
BMY LLY BIIB
$6.49B 0.89 FOLLOWER